Experimental research on the local delivery of adriamycin incorporated into hydroxyapatite beads

Keiko Yamamura, Takashi Osada, Khoji Yano, Toshitaka Nabeshima, Hisashi Iwata, Toshihisa Yotsuyanagi

Research output: Contribution to journalArticle

Abstract

Various forms of hydroxyapatite(HAP) materials have been extensively developed for orthopedic and dental applications as bone grafts and bone substitutes. It seems useful to incorporate cancer chemotherapeutic agents into implant materials used in the sites of the bony defect postoperation of bone tumors, to control local recurrence. This study was conducted to investigate whether porous HAP is appropriate as a drug carrier for adriamycin(ADR) by determining the anticancer effects of ADR-HAP beads and release behavior of ADR from HAP beads. Porous HAP bead (8.48 mm in diameter, 531±0.7 mg in weight) was used as a model material, Various ADR-HAP beads(ADR 0.4∼6.0 mg/bead) were implanted s. c. into Sprague-Dawley rats at 6 day postinoculation of Swarm rat chondrosarcoma. ADR levels were determined using HPLC. ADR in the tumors released from ADR-HAP beads(6.0 mg/bead) were observed over a 13-week period. However, the diffusion of the drug to other organs such as heart and liver was very low compared with the level in the tumors. ADR HAP beads more than the dose of 1.0 mg/bead showed strong antitumor activities with dose of ADR. The dose of 6.0 mg/bead showed most efficacy, and no toxic death caused, which 98% growth inhibition on Day 31, and the survival advantage of 339% increase in life span were obtained. HAP is thus concluded to be usable not only as a bone graft but as an anticancer drug carrier for achieving high sustained local levels of the anticancer drug in the implanted site, together a low systemic level.

Original languageEnglish
Pages (from-to)453-459
Number of pages7
JournalDrug Delivery System
Volume8
Issue number6
DOIs
Publication statusPublished - 01-01-1993
Externally publishedYes

Fingerprint

Durapatite
Doxorubicin
Research
Drug Carriers
Bone and Bones
Neoplasms
Transplants
Bone Substitutes
Chondrosarcoma
Poisons
Pharmaceutical Preparations
Orthopedics
Sprague Dawley Rats
Tooth
High Pressure Liquid Chromatography
Weights and Measures
Recurrence
Liver

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

Yamamura, Keiko ; Osada, Takashi ; Yano, Khoji ; Nabeshima, Toshitaka ; Iwata, Hisashi ; Yotsuyanagi, Toshihisa. / Experimental research on the local delivery of adriamycin incorporated into hydroxyapatite beads. In: Drug Delivery System. 1993 ; Vol. 8, No. 6. pp. 453-459.
@article{389649db10724cc48bd3b9b718088536,
title = "Experimental research on the local delivery of adriamycin incorporated into hydroxyapatite beads",
abstract = "Various forms of hydroxyapatite(HAP) materials have been extensively developed for orthopedic and dental applications as bone grafts and bone substitutes. It seems useful to incorporate cancer chemotherapeutic agents into implant materials used in the sites of the bony defect postoperation of bone tumors, to control local recurrence. This study was conducted to investigate whether porous HAP is appropriate as a drug carrier for adriamycin(ADR) by determining the anticancer effects of ADR-HAP beads and release behavior of ADR from HAP beads. Porous HAP bead (8.48 mm in diameter, 531±0.7 mg in weight) was used as a model material, Various ADR-HAP beads(ADR 0.4∼6.0 mg/bead) were implanted s. c. into Sprague-Dawley rats at 6 day postinoculation of Swarm rat chondrosarcoma. ADR levels were determined using HPLC. ADR in the tumors released from ADR-HAP beads(6.0 mg/bead) were observed over a 13-week period. However, the diffusion of the drug to other organs such as heart and liver was very low compared with the level in the tumors. ADR HAP beads more than the dose of 1.0 mg/bead showed strong antitumor activities with dose of ADR. The dose of 6.0 mg/bead showed most efficacy, and no toxic death caused, which 98{\%} growth inhibition on Day 31, and the survival advantage of 339{\%} increase in life span were obtained. HAP is thus concluded to be usable not only as a bone graft but as an anticancer drug carrier for achieving high sustained local levels of the anticancer drug in the implanted site, together a low systemic level.",
author = "Keiko Yamamura and Takashi Osada and Khoji Yano and Toshitaka Nabeshima and Hisashi Iwata and Toshihisa Yotsuyanagi",
year = "1993",
month = "1",
day = "1",
doi = "10.2745/dds.8.453",
language = "English",
volume = "8",
pages = "453--459",
journal = "Drug Delivery System",
issn = "0913-5006",
publisher = "Japan Society of Drug Delivery System",
number = "6",

}

Experimental research on the local delivery of adriamycin incorporated into hydroxyapatite beads. / Yamamura, Keiko; Osada, Takashi; Yano, Khoji; Nabeshima, Toshitaka; Iwata, Hisashi; Yotsuyanagi, Toshihisa.

In: Drug Delivery System, Vol. 8, No. 6, 01.01.1993, p. 453-459.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Experimental research on the local delivery of adriamycin incorporated into hydroxyapatite beads

AU - Yamamura, Keiko

AU - Osada, Takashi

AU - Yano, Khoji

AU - Nabeshima, Toshitaka

AU - Iwata, Hisashi

AU - Yotsuyanagi, Toshihisa

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Various forms of hydroxyapatite(HAP) materials have been extensively developed for orthopedic and dental applications as bone grafts and bone substitutes. It seems useful to incorporate cancer chemotherapeutic agents into implant materials used in the sites of the bony defect postoperation of bone tumors, to control local recurrence. This study was conducted to investigate whether porous HAP is appropriate as a drug carrier for adriamycin(ADR) by determining the anticancer effects of ADR-HAP beads and release behavior of ADR from HAP beads. Porous HAP bead (8.48 mm in diameter, 531±0.7 mg in weight) was used as a model material, Various ADR-HAP beads(ADR 0.4∼6.0 mg/bead) were implanted s. c. into Sprague-Dawley rats at 6 day postinoculation of Swarm rat chondrosarcoma. ADR levels were determined using HPLC. ADR in the tumors released from ADR-HAP beads(6.0 mg/bead) were observed over a 13-week period. However, the diffusion of the drug to other organs such as heart and liver was very low compared with the level in the tumors. ADR HAP beads more than the dose of 1.0 mg/bead showed strong antitumor activities with dose of ADR. The dose of 6.0 mg/bead showed most efficacy, and no toxic death caused, which 98% growth inhibition on Day 31, and the survival advantage of 339% increase in life span were obtained. HAP is thus concluded to be usable not only as a bone graft but as an anticancer drug carrier for achieving high sustained local levels of the anticancer drug in the implanted site, together a low systemic level.

AB - Various forms of hydroxyapatite(HAP) materials have been extensively developed for orthopedic and dental applications as bone grafts and bone substitutes. It seems useful to incorporate cancer chemotherapeutic agents into implant materials used in the sites of the bony defect postoperation of bone tumors, to control local recurrence. This study was conducted to investigate whether porous HAP is appropriate as a drug carrier for adriamycin(ADR) by determining the anticancer effects of ADR-HAP beads and release behavior of ADR from HAP beads. Porous HAP bead (8.48 mm in diameter, 531±0.7 mg in weight) was used as a model material, Various ADR-HAP beads(ADR 0.4∼6.0 mg/bead) were implanted s. c. into Sprague-Dawley rats at 6 day postinoculation of Swarm rat chondrosarcoma. ADR levels were determined using HPLC. ADR in the tumors released from ADR-HAP beads(6.0 mg/bead) were observed over a 13-week period. However, the diffusion of the drug to other organs such as heart and liver was very low compared with the level in the tumors. ADR HAP beads more than the dose of 1.0 mg/bead showed strong antitumor activities with dose of ADR. The dose of 6.0 mg/bead showed most efficacy, and no toxic death caused, which 98% growth inhibition on Day 31, and the survival advantage of 339% increase in life span were obtained. HAP is thus concluded to be usable not only as a bone graft but as an anticancer drug carrier for achieving high sustained local levels of the anticancer drug in the implanted site, together a low systemic level.

UR - http://www.scopus.com/inward/record.url?scp=85024315038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024315038&partnerID=8YFLogxK

U2 - 10.2745/dds.8.453

DO - 10.2745/dds.8.453

M3 - Article

AN - SCOPUS:85024315038

VL - 8

SP - 453

EP - 459

JO - Drug Delivery System

JF - Drug Delivery System

SN - 0913-5006

IS - 6

ER -